Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02310360
Other study ID # S56186
Secondary ID
Status Active, not recruiting
Phase N/A
First received November 19, 2014
Last updated October 25, 2016
Start date November 2014
Est. completion date March 2017

Study information

Verified date October 2016
Source Universitaire Ziekenhuizen Leuven
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health Products
Study type Observational

Clinical Trial Summary

The purpose of this study is to investigate whether a combination of taste probes and food-related cues can induce dopamine release in striatal and extra-striatal brain regions in healthy subjects.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date March 2017
Est. primary completion date December 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Female

- 20 = BMI = 25

- Right handed

- Stable body weight for at least 3 consecutive months at start of study and no history of behavioral, therapeutic or surgical treatment aiming at or leading to weight loss/gain

- Subject understands the study procedures and agrees to participate in the study by giving written informed consent

Exclusion Criteria:

- Medical (current or history):

- Abdominal/thoracic surgery except appendectomy

- Gastrointestinal, endocrine (especially diabetes), or neurological diseases

- Cardiovascular, respiratory, renal or urinary diseases

- Hypertension

- Food or drug allergies

- Head trauma with loss of consciousness

- Psychiatric disorders (current or history):

- Eating disorders

- Psychotic disorders

- Major depressive disorder

- Somatoform disorder

- Emotional and/or restraint eating

- Treatment in the last 6 months with antidepressants (as MAO inhibitors), neuroleptics, sedative hypnotics, psychostimulants, glucocorticoids, appetite suppressants, estrogens, opiate, or dopamine medications. Oral contraception is allowed

- History of cannabis use or any other drug of abuse for at least 12 months prior to the study

- Intolerance of lactose

- Vegetarians

- Smoking and alcohol intake greater than 5 alcoholic units per week (one alcoholic unit = 10 gr ethanol)

- More than moderate exercise (> 30 min, five times per week of walking or equivalent)

- High caffeine intake (> 500 ml coffee daily or equivalent)

- Exposure to a significant amount (> 1mSv) of ionizing radiation in other research studies within the last 12 months

- Claustrophobia or too much uneasiness in limited spaces (in order tolerate confinement during PET scanning procedures)

- Inability or unwillingness to perform all of the study procedures, or if the subject is considered unsuitable in any way by the principal investigator

- Recent participation (< 30 days) or simultaneous participation in another clinical trial

- Any condition that would interfere with Magnetic Resonance Imaging (MRI) or PET studies (e.g., cochlear implant, metal fragments in eyes, cardiac pacemaker, neural stimulator, and metallic body inclusion or other metal implanted in the body which may interfere with MRI scanning)

- Anemia

- Pregnancy

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Intervention

Radiation:
Fallypride


Locations

Country Name City State
Belgium University Hospitals Leuven, campus Gasthuisberg Leuven

Sponsors (1)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary DA release in both striatal and extra-striatal brain regions A [18F]Fallypride PET protocol and the linearized simplified reference region model (LSSRM) kinetic model will be used to detect DA release. 1 year No
See also
  Status Clinical Trial Phase
Completed NCT01240018 - ProSat - Long Term Effect of Probiotics on Satiety N/A
Recruiting NCT05587127 - Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia N/A
Completed NCT02774486 - Efficacy and Safety of IQP-AK-102 in Reducing Appetite N/A
Completed NCT03322514 - Colonic Propionate, Appetite, and Weight Loss N/A
Completed NCT01965210 - The Effect of Dietary Fibre and Plant Protein on Appetite and Metabolic Function N/A
Completed NCT02487342 - Metabolic, Endocrine and Appetite-related Responses in Healthy, Adolescent Males After Acute and Daily Milk Consumption N/A
Completed NCT00912197 - Effect of Oligofructose on Appetite in Overweight Subjects N/A
Completed NCT03956732 - Effects of Milk Protein and Vitamin D on Children's Growth and Health N/A
Completed NCT03143868 - Role of Acute Exercise Modality on Appetite Regulation and Energy Intake N/A
Completed NCT04788069 - Effect of Sourdough Breads Consumption on Postprandial Responses, Satiety and Food Intake at Subsequent Meal N/A
Completed NCT01644539 - Brain Activity and Hormonal Changes During Food Administration N/A
Withdrawn NCT01152333 - The Role of GLP-1 in Satiety Perception in Humans N/A
Completed NCT03025997 - Lipid Encapsulation for Ileal Brake Activation N/A
Completed NCT01877460 - Sodium Alginate in Chocolate Milk, Satiety and Glycemic Control N/A
Completed NCT00826761 - ProSat - Effect of Probiotics on Satiety N/A
Completed NCT04345029 - Effectiveness of a Natural Ingredient on Appetite Regulation N/A
Completed NCT01259895 - Effects of Time of Sleep Restriction in Obesity N/A
Completed NCT00776256 - Effects of Oligofructose and Barley on Satiety and Energy Intake N/A
Recruiting NCT05610124 - Postprandial Glycemia and Satiety of Meals With Potatoes, With and Without Protein N/A
Active, not recruiting NCT02310347 - Influence of a Medicinal Cannabinoid Agonist on Responses to Food Images and Food Intake N/A